Clinical Manifestations of Acute COVID-19 in Previously Healthy Pediatric Patients Diagnosed by Rapid Antigen Screening in a Community-Based, Outpatient Primary Care Pediatrics Practice.

Background: The PediCenter and Niles Children's Clinic provide pediatric primary and urgent care services in central California. We remained open throughout the COVID-19 pandemic, providing scheduled well child-care and sick visits.

Methods: Beginning in September 2020, we implemented a COVID-19 screening program.

Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.

Objective: A variety of pharmacologic therapies are available or in development for the prevention of breast cancer recurrence. Assessing the value of these treatments is compromised by a paucity of data on the impact of recurrence on economic costs and survival. The purpose of this study was to shed light on these issues.

Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.

Objectives: Data from the Intergroup Exemestane Study (IES) suggest that switching to the aromatase inhibitor, exemestane, after 2 to 3 years of tamoxifen therapy prolongs disease-free survival versus continuing on tamoxifen therapy. We sought to evaluate the cost-effectiveness of this management strategy.

Methods: A Markov model was developed to predict patients' transitions across various health states based on treatment strategy (continuing tamoxifen vs.